Table 1.
Tumor donor patient characteristics for cachexia avatar lines
IDAge (yr)SexTMN stagingaCA19.9BMI (kg/m2)6M WLAvatar hIL-6 (pg/ml)
S002 84 M T3, N1, Mx 97 29.6 −17.3% >700  
S004 84 F T3, N1 200 27.3 14.7% - 
S005 70 F T1, N1 103 26.9 −10.0% - 
S016 75 M T3, N1 2,252 21.7 −11.9% - 
S017 69 M T3, N1 25 25.6 −3.2% 1.94 ± 0.95 
S018 68 M T3, N1, Mx 544 26.6 −7.2% - 
S035 65 M T2, N1 61 49.1 −30.6% 513.9 ± 152.9 
S037 82 F T3, N0, Mx 11 27 −4.7% - 
IDAge (yr)SexTMN stagingaCA19.9BMI (kg/m2)6M WLAvatar hIL-6 (pg/ml)
S002 84 M T3, N1, Mx 97 29.6 −17.3% >700  
S004 84 F T3, N1 200 27.3 14.7% - 
S005 70 F T1, N1 103 26.9 −10.0% - 
S016 75 M T3, N1 2,252 21.7 −11.9% - 
S017 69 M T3, N1 25 25.6 −3.2% 1.94 ± 0.95 
S018 68 M T3, N1, Mx 544 26.6 −7.2% - 
S035 65 M T2, N1 61 49.1 −30.6% 513.9 ± 152.9 
S037 82 F T3, N0, Mx 11 27 −4.7% - 

BMI, body mass index; F, female; hIL, human IL; M, male; 6M WL, 6-mo weight loss.

a

Pathological Tumor Node Metastasis Staging: T1 in pancreas with tumor <2 cm; T2 in pancreas and 2 cm < tumor < 4 cm; T3, beyond pancreas and tumor >4 cm. N0, no regional lymph nodes involved; N1, 1–3 regional lymph nodes involved; Mx, metastasis cannot be measured.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal